Share

Françoise Meunier, EORTC Director General, discusses issues facing cancer survivors

Prof Françoise Meunier, EORTC Director General, talked to eCancertv during the ESMO 2014 Congress about her recent article in the Financial Times on cancer and financial impact on cancer survivors.

Watch here the video of the interview

Early diagnosis, innovative drugs and integrated therapeutic strategies combining chemotherapy, surgery and radiotherapy have resulted in dramatic increases in cancer survival rates. In fact, EORTC trials have led to long term survival and cure for children with leukaemia and patients with Hodgkin’s lymphoma or testicular and breast cancers.

This success is good news, but it brings with a host of unanticipated issues facing cancer survivors, who are frequently excluded from insurance, mortgages and jobs.

The EORTC is active in addressing these issues. The 1st EORTC Cancer Survivorship Summit facilitated interactions between clinicians, researchers, social workers, patients, insurers, bankers and policy makers, and addressed second malignancies, cardiovascular disease, cognitive dysfunction, infertility/sexuality and psycho-social problems following cancer treatment. In light of the success of the first summit, a 2nd EORTC Cancer Survivorship Summit will be held 31 March – 01 April 2016 in Brussels, and in Spring 2015 the EORTC will organize a special cancer and employment forum for European employers, patients, and politicians.

John Bean, PhD
EORTC, Medical Science Writer

Back to news list

Related News

  • CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

  • EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials

  • New study confirms a key quality of life tool can be used with adolescents with cancer

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025

  • This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research

  • Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

  • EORTC’s presence at ESTRO 2026

  • Interview of ROSC Chair, Joost Vaerhoeff

  • Independent, academic cancer trials are vital to improve patient outcomes worldwide